ACAD
Income statement / Annual
Last year (2023), ACADIA Pharmaceuticals Inc.'s total revenue was $726.44 M,
an increase of 40.45% from the previous year.
In 2023, ACADIA Pharmaceuticals Inc.'s net income was -$61.29 M.
See ACADIA Pharmaceuticals Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$726.44 M
|
$517.24 M
|
$484.15 M
|
$441.76 M
|
$339.08 M
|
$223.81 M
|
$124.90 M
|
$17.33 M
|
$61,000.00
|
$120,000.00
|
Cost of Revenue |
$45.73 M |
$10.17 M |
$19.14 M |
$20.55 M |
$19.60 M |
$18.33 M |
$13.06 M |
$4.41 M |
$76.37 M |
$60.60 M |
Gross Profit |
$680.71 M |
$507.07 M |
$465.00 M |
$421.21 M |
$319.48 M |
$205.48 M |
$111.84 M |
$12.93 M |
-$76.31 M |
-$60.48 M |
Gross Profit Ratio |
0.94 |
0.98 |
0.96 |
0.95 |
0.94 |
0.92 |
0.9 |
0.75 |
-1250.95 |
-504.02 |
Research and Development
Expenses |
$351.62 M
|
$361.58 M
|
$239.42 M
|
$319.13 M
|
$240.39 M
|
$187.16 M
|
$149.19 M
|
$99.28 M
|
$73.87 M
|
$60.60 M
|
General & Administrative
Expenses |
$393.07 M
|
$363.59 M
|
$396.03 M
|
$388.66 M
|
$325.64 M
|
$265.76 M
|
$255.06 M
|
$186.46 M
|
$90.80 M
|
$32.75 M
|
Selling & Marketing
Expenses |
$9.40 M
|
$5.50 M
|
$41.80 M
|
$51.10 M
|
$38.30 M
|
$39.80 M
|
$15.60 M
|
$1.60 M
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$402.47 M
|
$369.09 M
|
$396.03 M
|
$388.66 M
|
$325.64 M
|
$265.76 M
|
$255.06 M
|
$186.46 M
|
$90.80 M
|
$32.75 M
|
Other Expenses |
$5.11 M |
$3.54 M |
$2.33 M |
-$997,000.00 |
$997,000.00 |
-$1.84 M |
$3.98 M |
$1.33 M |
$2.50 M |
$0.00 |
Operating Expenses |
$754.09 M |
$730.67 M |
$635.44 M |
$707.79 M |
$566.02 M |
$452.92 M |
$404.25 M |
$285.74 M |
$164.67 M |
$93.35 M |
Cost And Expenses |
$799.82 M |
$740.83 M |
$654.58 M |
$728.34 M |
$585.62 M |
$471.25 M |
$417.31 M |
$290.15 M |
$164.67 M |
$93.35 M |
Interest Income |
$17.23 M |
$6.61 M |
$591,000.00 |
$6.61 M |
$11.17 M |
$5.35 M |
$4.13 M |
$2.76 M |
$499,000.00 |
$755,000.00 |
Interest Expense |
$0.00 |
$6.61 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Depreciation &
Amortization |
$5.55 M
|
$2.03 M
|
$3.34 M
|
$2.93 M
|
$2.77 M
|
$3.01 M
|
$2.71 M
|
$1.83 M
|
$647,000.00
|
$206,000.00
|
EBITDA |
-$67.83 M
|
-$223.60 M
|
-$170.44 M
|
-$286.59 M
|
-$246.55 M
|
-$247.44 M
|
-$292.41 M
|
-$272.82 M
|
-$164.61 M
|
-$93.23 M
|
EBITDA Ratio |
-0.09 |
-0.43 |
-0.35 |
-0.65 |
-0.73 |
-1.11 |
-2.34 |
-15.74 |
-2698.56 |
-776.92 |
Operating Income Ratio
|
-0.1
|
-0.43
|
-0.35
|
-0.65
|
-0.73
|
-1.11
|
-2.34
|
-15.74
|
-2698.56
|
-776.92
|
Total Other
Income/Expenses Net |
$22.34 M
|
$10.15 M
|
$2.92 M
|
$5.61 M
|
$12.16 M
|
-$1.84 M
|
$4.13 M
|
$2.76 M
|
$499,000.00
|
$755,000.00
|
Income Before Tax |
-$51.04 M |
-$213.44 M |
-$167.52 M |
-$280.97 M |
-$234.38 M |
-$243.94 M |
-$288.28 M |
-$270.05 M |
-$164.11 M |
-$92.48 M |
Income Before Tax Ratio
|
-0.07
|
-0.41
|
-0.35
|
-0.64
|
-0.69
|
-1.09
|
-2.31
|
-15.58
|
-2690.38
|
-770.63
|
Income Tax Expense |
$10.25 M |
$2.53 M |
$351,000.00 |
$611,000.00 |
$876,000.00 |
$1.26 M |
$1.12 M |
$1.34 M |
$330,000.00 |
-$206,000.00 |
Net Income |
-$61.29 M |
-$215.98 M |
-$167.87 M |
-$281.58 M |
-$235.26 M |
-$245.19 M |
-$289.40 M |
-$271.39 M |
-$164.44 M |
-$92.48 M |
Net Income Ratio |
-0.08 |
-0.42 |
-0.35 |
-0.64 |
-0.69 |
-1.1 |
-2.32 |
-15.66 |
-2695.79 |
-770.63 |
EPS |
-0.37 |
-1.34 |
-1.05 |
-1.79 |
-1.6 |
-1.94 |
-2.36 |
-2.34 |
-1.63 |
-0.95 |
EPS Diluted |
-0.37 |
-1.34 |
-1.05 |
-1.79 |
-1.6 |
-1.94 |
-2.36 |
-2.34 |
-1.63 |
-0.95 |
Weighted Average Shares
Out |
$163.82 M
|
$161.68 M
|
$160.49 M
|
$157.33 M
|
$147.20 M
|
$126.58 M
|
$122.60 M
|
$115.86 M
|
$100.63 M
|
$97.25 M
|
Weighted Average Shares
Out Diluted |
$163.82 M
|
$161.68 M
|
$160.49 M
|
$157.33 M
|
$147.20 M
|
$126.58 M
|
$122.60 M
|
$115.86 M
|
$100.63 M
|
$97.25 M
|
Link |
|
|
|
|
|
|
|
|
|
|